Essex Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Essex Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-167,756	Closed	-$2.27M	–	476
2018 Q3	$2.27M	Sell	167,756 -431	-0.3%	-$4.52K	0.27%	106
2018 Q2	$2M	Sell	168,187 -205,830	-55%	-$2.57M	0.25%	115
2018 Q1	$4.2M	Buy	374,017 +286,710	+328%	+$2.51M	0.55%	43
2017 Q4	$583K	Buy	87,307 +14,311	+20%	+$111K	0.08%	259
2017 Q3	$598K	Sell	72,996 -119,049	-62%	-$743K	0.08%	252
2017 Q2	$862K	Buy	192,045 +151,273	+371%	+$791K	0.12%	213
2017 Q1	$225K	Buy	+40,772	New	+$178K	0.04%	314
2016 Q2	–	Sell	-60,575	Closed	-$492K	–	317
2016 Q1	$492K	Buy	+60,575	New	+$495K	0.08%	232

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Essex Investment Management's ADAP Position: Q4 2018 in Review

Essex Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2018, closing a stake of 167,756 shares — an estimated $2.27M sold.

Essex Investment Management first reported a position in ADAP in Q1 2016 and held it in 8 quarters. The position peaked at $4.2M in Q1 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2018.

Essex Investment Management reported no remaining Adaptimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
Essex Investment Management sold 167,756 Adaptimmune Therapeutics shares in Q4 2018, an estimated $2.27M.
Essex Investment Management first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 8 quarters.
Essex Investment Management's Adaptimmune Therapeutics position peaked at $4.2M in Q1 2018.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.